Why the last cases of sleeping sickness will be the hardest to eliminate
Briefly

Wilfried Mutombo Kalonji, after graduating from medical school in 2004, dedicated his life to helping the residents of Kasansa, DRC, as their sole physician.
Mutombo's experience with melarsoprol posed a grave challenge; the drug is toxic and has a distressing death rate of 5-10%, impacting both patients and their families.
Collaborating with the Drugs for Neglected Diseases Initiative, Mutombo works on developing safer treatments for sleeping sickness, which has seen a dramatic reduction in cases.
Acoziborole, a promising single-dose medication, has the potential to treat both confirmed cases and interrupt the transmission of sleeping sickness, altering the disease's trajectory.
Read at Nature
[
|
]